Developing first-in-class cardiovascular biopharmaceuticals that target natural repair pathways.

Press Releases

(Juventas Therapeutics, Inc. is formerly known as AcelleRX Therapeutics, Inc.)


February 3, 2016 - Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease


June 16, 2015 - Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy

May 26, 2015 - Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treatment

May 12, 2015 - Juventas Therapeutics Adds $13.5 million in New Financing and Expands Board of Directors


November 18, 2014 - Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia

November 12, 2014 - Juventas Therapeutics Phase II Clinical Study Results to be Presented at 2014 American Heart Association Scientific Sessions

October 28, 2014 - Juventas Therapeutics Strengthens Management Team with New Senior Vice President of Finance and Operations

August 12, 2014 - Juventas Therapeutics completes enrollment of Phase I/II RETRO-HF trial and demonstrates safety for retrograde infusion of JVS-100 in patients with heart failure

July 23, 2014 - Juventas Therapeutics strengthens leadership team by adding two industry veterans

May 19, 2014 - Juventas Therapeutics Data Demonstrates Significant Structural, Clinically Meaningful Benefit in Patients with Advanced Heart Failure

May 6, 2014 - Juventas Therapeutics to Present Top-Line Interim Results from Phase II STOP-HF Trial in Late-Breaking Oral Presentation at
European Society of Cardiology Heart Failure Congress

February 4, 2014 - Juventas Therapeutics initiates Phase II RETRO-HF clinical trial enrollment for patients with heart failure


October 28, 2013 - Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure

January 28, 2013 - Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development


August 20, 2012 - Juventas Therapeutics doses first patient in Phase II STOP-HF trial

July 17, 2012 - Juventas Therapeutics raises $22.2 million Series B Financing

May 15, 2012 - Juventas Therapeutics Enrolling Patients in Phase IIa STOP-CLI Clinical Trial

Jan. 30, 2012 - Juventas Therapeutics Reports One Year Data From Phase I Heart Failure Clinical Trial


April 26, 2011 - Juventas Therapeutics Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure

January 3, 2011 - Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia


April 5, 2010 - Juventas Therapeutics Enrolling Phase I Clinical Trial of JVS-100 for Patients with Heart Failure



October 9, 2008 - AcelleRX receives $6.9 million investment


July 30, 2007 - AcelleRX secures $1.5 million in financing